Markets
Robinhood logo
(Omar Marques/Getty Images)

Robinhood bull removes “buy” rating, cuts estimates

Morgan Stanley’s analysts covering brokerages also cut their price target and pivoted to more defensive, bond-focused firms like MarketAxess, Cboe, and CME.

Matt Phillips

Analysts at Morgan Stanley cut their “overweight” rating (basically, a buy) on Robinhood to “equal weight” (or hold), and downgraded their earnings forecast and price target for the stock, citing risks “that retail investors begin to disengage (for which we saw signs in March) in a period of prolonged market volatility and sharp drawdowns in broad market indices.” They wrote:

“In the context of a highly volatile and less certain macro environment with risks/uncertainty surrounding government policy, economic growth, and inflation, we lower our retail trading forecasts at the retail brokers and market infrastructure firms… and shift our preferences towards stocks that are less levered to retail trading.”

Morgan Stanley cut its price target for the shares to $40 from $90 — which was the second highest on Wall Street, according to Bloomberg data — and cut its earnings per share estimate for 2025 by 29%.

Robinhood has been hit hard since the stock market topped out on February 19, falling 40% through yesterday’s close, though the shares are bouncing higher today.

For what it’s worth, the bank also cut its ratings on Nasdaq, Virtu Financial, and Tradeweb to “equal weight” from “overweight,” and upgraded its rating on bond- and hedging-focused financial companies like CME Group, Cboe, and Marketaxess, shares that have done relatively well during the recent market tumult.

(Sherwood Media is an editorially independent subsidiary of Robinhood Markets Inc. I own Robinhood stock as part of my compensation.)

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.